IMHO, XCHO is currently doing better in the short term right now and it will continue to benefit from all the exposure of the Cobroxin sales and do well in the future too as this rollout continues as will NPHC very soon. NPHC holds all the rights and patents to Cobroxin/Nyloxin OTC & Nyloxin RX, along with everything in their pipeline, which is astounding! They are also gearing up to go worldwide and we have not heard yet how that will be distributed and with who. Now given those facts and the fact that they hold all the cards in this deal, I would have to side with probability they have the better opportunity to have greater success in the long term, but that is not to say XCHO will not do well also. My best advice would be to buy shares of both which many have here and then enjoy the ride up with both XCHO & NPHC. I hope that helps Jerry.